Which has higher valuation and earnings, CDRE or DCTH?

Cadre has higher revenue and earnings than Delcath Systems. Cadre is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cadre $610.31M 2.12 $44.14M $0.89 33.92 Delcath Systems $85.23M 4.43 $2.70M $0.01 1,094.00

Is CDRE or DCTH more profitable?

Cadre has a net margin of 5.80% compared to Delcath Systems' net margin of 0.62%. Cadre's return on equity of 12.39% beat Delcath Systems' return on equity. Company Net Margins Return on Equity Return on Assets Cadre 5.80% 12.39% 5.08% Delcath Systems 0.62% 0.51% 0.46%

Is ENOV or DCTH more profitable?

Delcath Systems has a net margin of 0.62% compared to Enovis' net margin of -49.92%. Enovis' return on equity of 10.32% beat Delcath Systems' return on equity. Company Net Margins Return on Equity Return on Assets Enovis -49.92% 10.32% 4.57% Delcath Systems 0.62% 0.51% 0.46%

Delcath Systems (DCTH) Competitors

$10.94 +0.27 (+2.53%)

Closing price 06/8/2026 04:00 PM Eastern

Extended Trading

$11.10 +0.16 (+1.48%)

As of 06/8/2026 07:55 PM Eastern

Compare

DCTH vs. EYE, CDRE, ENOV, KMTS, and BLFS

Should you buy Delcath Systems stock or one of its competitors? MarketBeat compares Delcath Systems with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Delcath Systems include National Vision (EYE), Cadre (CDRE), Enovis (ENOV), Kestra Medical Technologies (KMTS), and BioLife Solutions (BLFS). These companies are all part of the "medical equipment" industry.

How does Delcath Systems compare to National Vision?

National Vision (NASDAQ:EYE) and Delcath Systems (NASDAQ:DCTH) are both small-cap medical equipment companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk.

National Vision has higher revenue and earnings than Delcath Systems. National Vision is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
National Vision	$1.99B	0.65	$29.60M	$0.57	28.33
Delcath Systems	$85.23M	4.43	$2.70M	$0.01	1,094.00

National Vision has a net margin of 2.31% compared to Delcath Systems' net margin of 0.62%. National Vision's return on equity of 6.41% beat Delcath Systems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
National Vision	2.31%	6.41%	2.81%
Delcath Systems	0.62%	0.51%	0.46%

In the previous week, National Vision had 2 more articles in the media than Delcath Systems. MarketBeat recorded 2 mentions for National Vision and 0 mentions for Delcath Systems. National Vision's average media sentiment score of 1.04 beat Delcath Systems' score of 0.00 indicating that National Vision is being referred to more favorably in the media.

Company	Overall Sentiment
National Vision	Positive
Delcath Systems	Neutral

National Vision has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market. Comparatively, Delcath Systems has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market.

61.1% of Delcath Systems shares are owned by institutional investors. 2.4% of National Vision shares are owned by company insiders. Comparatively, 19.4% of Delcath Systems shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

National Vision currently has a consensus price target of $30.08, indicating a potential upside of 86.27%. Delcath Systems has a consensus price target of $22.50, indicating a potential upside of 105.67%. Given Delcath Systems' higher probable upside, analysts clearly believe Delcath Systems is more favorable than National Vision.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
National Vision	0 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.58
Delcath Systems	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

National Vision beats Delcath Systems on 11 of the 16 factors compared between the two stocks.

How does Delcath Systems compare to Cadre?

Cadre (NYSE:CDRE) and Delcath Systems (NASDAQ:DCTH) are both small-cap medical equipment companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations.

44.0% of Cadre shares are held by institutional investors. Comparatively, 61.1% of Delcath Systems shares are held by institutional investors. 30.1% of Cadre shares are held by company insiders. Comparatively, 19.4% of Delcath Systems shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Cadre had 5 more articles in the media than Delcath Systems. MarketBeat recorded 5 mentions for Cadre and 0 mentions for Delcath Systems. Cadre's average media sentiment score of 0.61 beat Delcath Systems' score of 0.00 indicating that Cadre is being referred to more favorably in the media.

Company	Overall Sentiment
Cadre	Positive
Delcath Systems	Neutral

Cadre has higher revenue and earnings than Delcath Systems. Cadre is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cadre	$610.31M	2.12	$44.14M	$0.89	33.92
Delcath Systems	$85.23M	4.43	$2.70M	$0.01	1,094.00

Cadre currently has a consensus target price of $39.75, suggesting a potential upside of 31.67%. Delcath Systems has a consensus target price of $22.50, suggesting a potential upside of 105.67%. Given Delcath Systems' higher probable upside, analysts plainly believe Delcath Systems is more favorable than Cadre.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadre	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57
Delcath Systems	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

Cadre has a beta of 1.32, suggesting that its share price is 32% more volatile than the broader market. Comparatively, Delcath Systems has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market.

Cadre has a net margin of 5.80% compared to Delcath Systems' net margin of 0.62%. Cadre's return on equity of 12.39% beat Delcath Systems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cadre	5.80%	12.39%	5.08%
Delcath Systems	0.62%	0.51%	0.46%

Summary

Cadre beats Delcath Systems on 12 of the 17 factors compared between the two stocks.

How does Delcath Systems compare to Enovis?

Enovis (NYSE:ENOV) and Delcath Systems (NASDAQ:DCTH) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends, media sentiment and analyst recommendations.

Enovis presently has a consensus price target of $44.50, suggesting a potential upside of 88.15%. Delcath Systems has a consensus price target of $22.50, suggesting a potential upside of 105.67%. Given Delcath Systems' higher possible upside, analysts clearly believe Delcath Systems is more favorable than Enovis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enovis	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Delcath Systems	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

Enovis has a beta of 1.38, suggesting that its stock price is 38% more volatile than the broader market. Comparatively, Delcath Systems has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market.

Delcath Systems has a net margin of 0.62% compared to Enovis' net margin of -49.92%. Enovis' return on equity of 10.32% beat Delcath Systems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enovis	-49.92%	10.32%	4.57%
Delcath Systems	0.62%	0.51%	0.46%

In the previous week, Enovis had 11 more articles in the media than Delcath Systems. MarketBeat recorded 11 mentions for Enovis and 0 mentions for Delcath Systems. Enovis' average media sentiment score of 0.36 beat Delcath Systems' score of 0.00 indicating that Enovis is being referred to more favorably in the media.

Company	Overall Sentiment
Enovis	Neutral
Delcath Systems	Neutral

Delcath Systems has lower revenue, but higher earnings than Enovis. Enovis is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enovis	$2.25B	0.61	-$1.18B	-$19.88	N/A
Delcath Systems	$85.23M	4.43	$2.70M	$0.01	1,094.00

98.5% of Enovis shares are held by institutional investors. Comparatively, 61.1% of Delcath Systems shares are held by institutional investors. 2.9% of Enovis shares are held by insiders. Comparatively, 19.4% of Delcath Systems shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Enovis beats Delcath Systems on 9 of the 16 factors compared between the two stocks.

How does Delcath Systems compare to Kestra Medical Technologies?

Delcath Systems (NASDAQ:DCTH) and Kestra Medical Technologies (NASDAQ:KMTS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

In the previous week, Kestra Medical Technologies had 1 more articles in the media than Delcath Systems. MarketBeat recorded 1 mentions for Kestra Medical Technologies and 0 mentions for Delcath Systems. Delcath Systems' average media sentiment score of 0.00 beat Kestra Medical Technologies' score of -0.71 indicating that Delcath Systems is being referred to more favorably in the media.

Company	Overall Sentiment
Delcath Systems	Neutral
Kestra Medical Technologies	Negative

61.1% of Delcath Systems shares are owned by institutional investors. 19.4% of Delcath Systems shares are owned by company insiders. Comparatively, 3.6% of Kestra Medical Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Delcath Systems has higher revenue and earnings than Kestra Medical Technologies. Kestra Medical Technologies is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Delcath Systems	$85.23M	4.43	$2.70M	$0.01	1,094.00
Kestra Medical Technologies	$59.81M	19.26	-$113.81M	-$3.96	N/A

Delcath Systems presently has a consensus target price of $22.50, suggesting a potential upside of 105.67%. Kestra Medical Technologies has a consensus target price of $27.40, suggesting a potential upside of 38.80%. Given Delcath Systems' stronger consensus rating and higher possible upside, research analysts clearly believe Delcath Systems is more favorable than Kestra Medical Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Delcath Systems	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43
Kestra Medical Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Delcath Systems has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market. Comparatively, Kestra Medical Technologies has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market.

Delcath Systems has a net margin of 0.62% compared to Kestra Medical Technologies' net margin of -171.87%. Delcath Systems' return on equity of 0.51% beat Kestra Medical Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Delcath Systems	0.62%	0.51%	0.46%
Kestra Medical Technologies	-171.87%	-65.49%	-46.39%

Summary

Delcath Systems beats Kestra Medical Technologies on 13 of the 16 factors compared between the two stocks.

How does Delcath Systems compare to BioLife Solutions?

Delcath Systems (NASDAQ:DCTH) and BioLife Solutions (NASDAQ:BLFS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership.

Delcath Systems has higher earnings, but lower revenue than BioLife Solutions. BioLife Solutions is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Delcath Systems	$85.23M	4.43	$2.70M	$0.01	1,094.00
BioLife Solutions	$96.21M	13.25	-$4.59M	-$0.08	N/A

61.1% of Delcath Systems shares are held by institutional investors. Comparatively, 93.2% of BioLife Solutions shares are held by institutional investors. 19.4% of Delcath Systems shares are held by insiders. Comparatively, 2.2% of BioLife Solutions shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Delcath Systems has a net margin of 0.62% compared to BioLife Solutions' net margin of -2.80%. BioLife Solutions' return on equity of 1.81% beat Delcath Systems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Delcath Systems	0.62%	0.51%	0.46%
BioLife Solutions	-2.80%	1.81%	1.65%

In the previous week, BioLife Solutions had 7 more articles in the media than Delcath Systems. MarketBeat recorded 7 mentions for BioLife Solutions and 0 mentions for Delcath Systems. BioLife Solutions' average media sentiment score of 0.17 beat Delcath Systems' score of 0.00 indicating that BioLife Solutions is being referred to more favorably in the news media.

Company	Overall Sentiment
Delcath Systems	Neutral
BioLife Solutions	Neutral

Delcath Systems presently has a consensus price target of $22.50, indicating a potential upside of 105.67%. BioLife Solutions has a consensus price target of $32.00, indicating a potential upside of 22.61%. Given Delcath Systems' stronger consensus rating and higher probable upside, equities analysts plainly believe Delcath Systems is more favorable than BioLife Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Delcath Systems	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43
BioLife Solutions	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Delcath Systems has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market. Comparatively, BioLife Solutions has a beta of 2, indicating that its share price is 100% more volatile than the broader market.

Summary

Delcath Systems and BioLife Solutions tied by winning 8 of the 16 factors compared between the two stocks.

Get Delcath Systems News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DCTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DCTH vs. The Competition

Export

Metric	Delcath Systems	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$368.35M	$7.25B	$6.49B	$11.99B
Dividend Yield	N/A	1.19%	2.67%	5.57%
P/E Ratio	1,094.00	46.41	23.68	23.74
Price / Sales	4.43	72.51	507.33	108.39
Price / Cash	204.12	25.19	26.99	37.25
Price / Book	3.47	6.89	10.28	6.78
Net Income	$2.70M	$159.22M	$3.57B	$337.51M
7 Day Performance	3.89%	-2.53%	0.28%	-2.34%
1 Month Performance	-4.70%	2.25%	3.27%	1.88%
1 Year Performance	-31.41%	-3.61%	22.22%	25.55%

Delcath Systems Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DCTH Delcath Systems	1.9439 of 5 stars	$10.94 +2.5%	$22.50 +105.7%	-33.2%	$368.35M	$85.23M	1,094.00	60	High Trading Volume
EYE National Vision	4.5545 of 5 stars	$15.87 -5.2%	$30.08 +89.5%	-23.2%	$1.34B	$2.02B	28.11	13,138	Positive News
CDRE Cadre	4.634 of 5 stars	$30.12 -3.3%	$39.75 +32.0%	-12.6%	$1.31B	$635.63M	34.08	2,533
ENOV Enovis	4.4884 of 5 stars	$21.47 -5.3%	$44.50 +107.3%	-25.6%	$1.25B	$2.28B	N/A	7,802	News Coverage Analyst Downgrade
KMTS Kestra Medical Technologies	2.1475 of 5 stars	$19.24 -9.5%	$27.40 +42.4%	-4.6%	$1.24B	$59.81M	N/A	300	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DCTH) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Delcath Systems (DCTH) Competitors

DCTH vs. EYE, CDRE, ENOV, KMTS, and BLFS

How does Delcath Systems compare to National Vision?

Summary

How does Delcath Systems compare to Cadre?

Summary

How does Delcath Systems compare to Enovis?

Summary

How does Delcath Systems compare to Kestra Medical Technologies?

Summary

How does Delcath Systems compare to BioLife Solutions?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCTH vs. The Competition

Delcath Systems Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Delcath Systems (DCTH) Competitors

DCTH vs. EYE, CDRE, ENOV, KMTS, and BLFS

How does Delcath Systems compare to National Vision?

Which has preferable valuation and earnings, EYE or DCTH?

Is EYE or DCTH more profitable?

Does the media refer more to EYE or DCTH?

Which has more volatility & risk, EYE or DCTH?

Do insiders and institutionals believe in EYE or DCTH?

Do analysts rate EYE or DCTH?

Summary

How does Delcath Systems compare to Cadre?

Do insiders & institutionals believe in CDRE or DCTH?

Does the media prefer CDRE or DCTH?

Which has higher valuation and earnings, CDRE or DCTH?

Do analysts rate CDRE or DCTH?

Which has more volatility and risk, CDRE or DCTH?

Is CDRE or DCTH more profitable?

Summary

How does Delcath Systems compare to Enovis?

Do analysts rate ENOV or DCTH?

Which has more volatility & risk, ENOV or DCTH?

Is ENOV or DCTH more profitable?

Does the media favor ENOV or DCTH?

Which has preferable earnings & valuation, ENOV or DCTH?

Do insiders and institutionals believe in ENOV or DCTH?

Summary

How does Delcath Systems compare to Kestra Medical Technologies?

Does the media refer more to DCTH or KMTS?

Do insiders & institutionals hold more shares of DCTH or KMTS?

Which has preferable valuation & earnings, DCTH or KMTS?

Do analysts rate DCTH or KMTS?

Which has more risk and volatility, DCTH or KMTS?

Is DCTH or KMTS more profitable?

Summary

How does Delcath Systems compare to BioLife Solutions?

Which has higher earnings and valuation, DCTH or BLFS?

Do insiders & institutionals have more ownership in DCTH or BLFS?

Is DCTH or BLFS more profitable?

Does the media prefer DCTH or BLFS?

Do analysts recommend DCTH or BLFS?

Which has more risk and volatility, DCTH or BLFS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCTH vs. The Competition

Delcath Systems Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools